Literature DB >> 300842

Relation of protease inhibitor phenotypes to obstructive lung diseases in a community.

J O Morse, M D Lebowitz, R J Knudson, B Burrows.   

Abstract

To examine the relative risk for the development of obstructive lung disease in persons heterozygous for alpha1-antitrypsin deficiency, we determined protease inhibitor phenotypes in 2944 subjects in a general community population. Phenotype M was found in 89.5 per cent, MS in 7.1 per cent, and MZ in 3.0 per cent of the population. There were two persons of phenotype Z and six of phenotype SZ. The study also included respiratory questionnaires and spirometry. There were no statistically significant differences in the prevalence of respiratory symptoms and diagnoses or of ventilatory impairment among the three major phenotype groups (M, MS and MZ), nor were there differences in the rates of deterioration of function with age or smoking. Consequently, we do not consider population screening for heterozygous alpha1-antitrypsin deficiency to be worthwhile.

Entities:  

Mesh:

Year:  1977        PMID: 300842     DOI: 10.1056/NEJM197705262962102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  20 in total

Review 1.  Alpha-1-antitrypsin deficiency: what next?

Authors:  R A Stockley
Journal:  Thorax       Date:  2000-07       Impact factor: 9.139

Review 2.  alpha-1-Antitrypsin and the pathogenesis of emphysema.

Authors:  R A Stockley
Journal:  Lung       Date:  1987       Impact factor: 2.584

3.  Smoking and intermediate alpha1-antitrypsin deficiency and lung function in middle-aged men.

Authors:  C Larsson; S Eriksson; H Dirksen
Journal:  Br Med J       Date:  1977-10-08

4.  α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts.

Authors:  Inga-Cecilie Sørheim; Per Bakke; Amund Gulsvik; Sreekumar G Pillai; Ane Johannessen; Per I Gaarder; Edward J Campbell; Alvar Agustí; Peter M A Calverley; Claudio F Donner; Barry J Make; Stephen I Rennard; Jørgen Vestbo; Emiel F M Wouters; Peter D Paré; Robert D Levy; Harvey O Coxson; David A Lomas; Craig P Hersh; Edwin K Silverman
Journal:  Chest       Date:  2010-07-01       Impact factor: 9.410

5.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

6.  [Prenatal diagnosis of alpha-1-antitrypsin phenotype. Case record and prognosis in severe alpha-antitrypsin deficiency Pi ZZ (author's transl)].

Authors:  S L Roth; K Havemann; G A Martini; H G Benkmann; H W Goedde; M Gramse; U Hillig; G Hug; R Keitzer; E Latta; R Rauskolb
Journal:  Klin Wochenschr       Date:  1980-06-16

7.  Diagnosing alpha-1 antitrypsin deficiency: does it prevent or improve the course of COPD?

Authors:  Irma Godoy
Journal:  J Bras Pneumol       Date:  2016 Sep-Oct       Impact factor: 2.624

8.  Lung distensibility and airway function in intermediate alpha 1-antitrypsin deficiency (Pi MZ).

Authors:  S F Tattersall; R P Pereira; D Hunter; G Blundell; N B Pride
Journal:  Thorax       Date:  1979-10       Impact factor: 9.139

9.  Pulmonary emphysema associated with the FZ alpha 1-antitrypsin phenotype.

Authors:  D W Cockcroft; R K Tennent; S L Horne
Journal:  Can Med Assoc J       Date:  1981-03-15       Impact factor: 8.262

Review 10.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.